Genprex Inc
For the period ended Dec 31, 2024. Filed Apr 1, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 1, 2025
GNPX$2.06-0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| Year Ended | ||
|---|---|---|
| December 31, | ||
| 2024 | 2023 | |
| Revenues | $— | $— |
| Cost and expenses: | ||
| Depreciation | 6,693 | 15,004 |
| Research and development | 10,535,446 | 17,616,605 |
| General and administrative | 10,632,028 | 13,425,285 |
| Total costs and expenses | 21,174,167 | 31,056,894 |
| Operating loss | (21,174,167) | (31,056,894) |
| Interest income | 63,574 | 215,109 |
| Realized loss | (570) | (18,676) |
| Net loss | (21,111,163) | (30,860,461) |
| Deemed dividend related to warrant modification | (277,119) | — |
| Net loss attributable to common stockholders | $(21,388,282) | $(30,860,461) |
| Net loss per share applicable to common stockholders — basic and diluted | $(5.34) | $(22.56) |
| Weighted average number of common shares — basic and diluted | 4,005,994 | 1,367,747 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.